Prevalence of pretreatment drug resistance in persons initiating and reinitiating antiretroviral therapy in Sri Lanka: results from a national representative survey
Journal of Antimicrobial Chemotherapy · 2023
DOI: 10.1093/jac/dkad110 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von J Elwitigala und 11 weiteren Autor:innen. Beteiligte Einrichtung: National STD/AIDS Control Programme, Ministry of Health, Colombo, Sri Lanka. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV-1, Sexual and Gender Minorities, HIV Infections. Die Arbeit nennt 18 Literaturangaben. Gefördert von: Global Fund, Tuberculosis and Malaria.
Abstract (Originalsprache)
Background
We conducted a nationwide cross-sectional study to estimate pretreatment drug resistance (PDR) prevalence in adults initiating ART in Sri Lanka following the WHO’s recommendations.
Methods
HIV drug resistance was determined on dried blood spots (DBSs) using population-based sequencing of the protease and reverse transcriptase genes and interpretation was based on Stanford HIVdb v9.0. Analyses were weighted to adjust for multistage sampling and genotypic failure rate. We used logistic regression to assess differences between groups.
Results
Overall, in 10% (15 of 150) of patients initiating ART, HIV drug resistance mutations were detected. The prevalence of resistance to NNRTI drugs efavirenz/nevirapine was 8.4% (95% CI 4.6–15.0) but differed among those reporting having prior antiretroviral (ARV) exposure (24.4%, 95% CI 13.8–39.5) compared with 4.6% (95% CI 1.6–12.8) for those reporting as being ARV naive (OR 4.6, 95% CI 1.3–16.6, P = 0.021). PDR to efavirenz/nevirapine was also nearly twice as high among women (14.1%, 95% CI 6.1–29.4) compared with men (7.0%, 95% CI 3.1–14.7) (P = 0.340) and three times high among heterosexuals (10.4%, 95% CI 2.4–35.4) compared with MSM (3.8%, 95% CI 1.1–12.7) (P = 0.028). NRTI PDR prevalence was 3.8% (95% CI 1.1–12.1) and no PI PDR was observed in the study.
Conclusions
A high prevalence of efavirenz/nevirapine PDR was reported, especially in patients with prior ARV exposure, in women and those reporting being heterosexual. These findings highlight the need to fast-track the transition to the WHO-recommended dolutegravir-based first-line ART.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National STD/AIDS Control Programme, Ministry of Health, Colombo, Sri Lanka.
- Amsterdam Institute for Global Health and Development, and Department of Global Health, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
- HIV Drug Resistance Laboratory, National AIDS Research Institute, Pune, India.
ORCID-Profile: S C Inzaule
Förderung
- Global Fund
- Tuberculosis and Malaria
Zitieren
APA
Elwitigala, J., Rajapaksa, L., Inzaule, S. C., Ariyaratne, K. A. M., Jayasena, S., Kurle, S., Patil, A., Kale, D., Siriwardna, L., Samaraweera, G., Perera, H., & Jayakody, C. (2023). Prevalence of pretreatment drug resistance in persons initiating and reinitiating antiretroviral therapy in Sri Lanka: results from a national representative survey. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkad110
Vancouver
Elwitigala J, Rajapaksa L, Inzaule SC, Ariyaratne KAM, Jayasena S, Kurle S, et al. Prevalence of pretreatment drug resistance in persons initiating and reinitiating antiretroviral therapy in Sri Lanka: results from a national representative survey. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkad110
BibTeX
@article{Elwitigala2023,
author = {Elwitigala, J and Rajapaksa, L and Inzaule, S C and Ariyaratne, K A M and Jayasena, S and Kurle, S and Patil, A and Kale, D and Siriwardna, L and Samaraweera, G and Perera, H and Jayakody, C},
title = {Prevalence of pretreatment drug resistance in persons initiating and reinitiating antiretroviral therapy in Sri Lanka: results from a national representative survey},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2023},
doi = {10.1093/jac/dkad110}
}
EUVIMED